News and Press Releases
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 IMC-M113V was well tolerated, with no dose-limiting toxicities Signals of dose-dependent...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 10, 2025
Carbon Minimal pressurised Metered Dose Inhalers (pMDIs) could save up to 619,000 tonnes of emissions each year, representing up to 7%-10% of NHS Net Zero targets
At a national level, seamless transitioning to a range of carbon minimal pMDIs could save between 415,000 and 619,000 tCO₂e annually, reducing carbon emissions to the equivalent financial value of...
Category: Drug Delivery, Manufacturing and Packing
Posted: March 10, 2025
Vertex Announces UK MHRA Approval of ALYFTREK (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulatorfor the Treatment of Cystic Fibrosis
Deutivacaftor/tezacaftor/vanzacaftor approved for people with cystic fibrosis 6 years and older with at least one responsive mutation in the CFTR gene, including additional mutations not previously approved with other CFTR...
Category: Drug Discovery, Other, Pharmaceutical
Posted: March 7, 2025
Innovaderm Research Rebrands as Indero, a dual-focus CRO
7 March 2025 -- Quebec, Canada -- Innovaderm, a leading clinical research organization (CRO), is excited to reveal a major rebranding to Indero, with immediate effect. The new brand identity...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 7, 2025
Cold Chain Technologies Acquires Global Cold Chain Solutions,Expanding Its Asia Pacific Presence & Capabilities
5 March 2025 – Franklin, MA, US and Melbourne, Australia – Cold Chain Technologies (“CCT”), a leading global provider of advanced thermal packaging and digital monitoring solutions for the transportation of temperature-sensitive life sciences...
Category: Logistics, Manufacturing and Packing
Posted: March 7, 2025
ProBioGen Successfully Completes CMC Development Milestones for Marea’s Promising Acromegaly Therapeutic
6 March 2025 -- Berlin, Germany -- ProBioGen and Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 6, 2025
NHS patients receive medicines manufactured by Octapharma using UK-donated plasma for the first time in almost 30 years
The sole manufacturer for the UK’s Plasma for Medicines (PfM) programme is supporting the Department of Health and Social Care, NHS England, and NHS Blood and Transplant to build resilience...
Category: Other, Pharmaceutical
Posted: March 6, 2025
HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China
6 March 2025 -- Hong Kong, Shanghai and New Jersey, US -- HUTCHMED (China) Limitedtoday announces that it has completed enrollment of its a Phase II trial of fanregratinib (HMPL-453)...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: March 6, 2025
Cherwell supports microbiological environmental monitoring best practices conference
Cleanroom microbiology experts on hand at Pharmig’s specialist conference to discuss assessment of sterility in pharmaceutical manufacturing facilities 6 March 2025 -- Bicester, UK -- Cherwell, cleanroom microbiology solutions expert,...
Category: BioManufacturing, Biotechnology, Other, Pharmaceutical
Posted: March 6, 2025
Launton Business Centre Murdock Rd, Bicester OX26 4XB
Bioxodes obtains Orphan Drug Designation for hemorrhagic stroke therapeutic candidate in US and Europe
FDA, EMA grant BIOX-101 ODD status to treat intracerebral hemorrhagic stroke (ICH) ODD status may expedite drug candidate development and approvals BIOX-101 interim Phase 2a data in ICH imminent. 5...
Category: Drug Discovery, Other, Pharmaceutical
Posted: March 5, 2025
Micreos Pharmaceuticals partners with Biologics CDMO Northway Biotech for its Engineered Endolysin therapeutic manufacturing program
4 March 2025 -- Zug, Switzerland, and Vilnius, Lithuania -- Micreos Pharmaceuticals AG ("Micreos"), a preclinical-stage biopharmaceutical company, specializing in developing Engineered Endolysin therapies to target harmful pathogens that cause...
Category: BioManufacturing, Biotechnology, Other, Pharmaceutical
Posted: March 4, 2025
Medable Achieves Landmark CNIL Approval, Expanding Access for Digital Clinical Trials Across the European Union
4 March 2025 -- California, US -- Medable Inc., a leading provider of clinical development technology, announced that its eConsent and eCOA solutions have been approved for use in two...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 4, 2025
Centauri Therapeutics selects first clinical candidate, for immunotherapeutic treatment of Gram-negative bacterial infections
Lead candidate in the ABX-01 programme to progress into first-in-human clinical studies Programme designed to treat Gram-negative bacterial lung infections in the most vulnerable patients. 4 March 2025 -- London,...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 4, 2025
FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics
This innovative method has the potential to unlock new treatment options for chronic conditions driven by mitochondrial dysregulation. 4 March 2025 -- Texas, US -- FibroBiologics, Inc, a clinical-stage biotechnology...
Category: Biotechnology, Other, Pharmaceutical
Posted: March 4, 2025
Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
4 March 2025 -- New York, US -- Tiziana Life Sciences, Ltd, a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 4, 2025
Tiziana Life Sciences 14/15 Conduit Street London W1S 2XJ United Kingdom
